Loomis, Sayles & Company
SWAV

Loomis, Sayles & Company’s Shockwave Medical, Inc. Common Stock SWAV Stock Holding History

Loomis, Sayles & Company’s Portfolio SWAV Stock Details SWAV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-109,942
Closed -$35.8M – 762
2024
Q1 		$35.8M Buy
109,942
+109,909
+333,058% +$27M 0.05% 171
2023
Q4 		$6K Buy
+33
New +$6.24K ﹤0.01% 870

Other funds holding SWAV

SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return
UWS
Unique Wealth Strategies Burr Ridge, Illinois $275M AUM 29.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Loomis, Sayles & Company's SWAV Position: Q2 2024 in Review

Loomis, Sayles & Company sold out of Shockwave Medical, Inc. Common Stock (SWAV) in Q2 2024, closing a stake of 109,942 shares — an estimated $35.8M sold.

Loomis, Sayles & Company first reported a position in SWAV in Q4 2023 and held it in 2 quarters. The position peaked at $35.8M in Q1 2024. 7 funds tracked by Wall St. Rank hold SWAV as of Q2 2024.

  • Loomis, Sayles & Company reported no remaining Shockwave Medical, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 109,942 Shockwave Medical, Inc. Common Stock shares in Q2 2024, an estimated $35.8M.
  • Loomis, Sayles & Company first reported a position in Shockwave Medical, Inc. Common Stock in Q4 2023 and held it in 2 quarters.
  • Loomis, Sayles & Company's Shockwave Medical, Inc. Common Stock position peaked at $35.8M in Q1 2024.
  • 7 funds tracked by Wall St. Rank held Shockwave Medical, Inc. Common Stock as of Q2 2024.

Based on Loomis, Sayles & Company's 13F filing for Q2 2024, filed 13 Aug 2024.